Complications after lymph node removal during lung cancer surgery
Studies complications from lymph node removal in people having surgery for lung cancer.
Plain-language title generated from the registry record
Registry title: Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).
Key facts
- Where
- Ulyanovsk, RussiaSee the site
Where in Russia
- Regional Clinical Oncology DispensaryUlyanovsk, RussiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regional Clinical Oncology Dispensary
- Trial code
- NCT07401498
- Record updated
- 10 February 2026
- Original description
Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited.Read full original descriptionShow less
A Multicenter Prospective Observational Study of the Incidence and Predictors of Complications Directly Related to Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).
Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited.
Objective: To assess trends and characteristics of projects directly related to Lymph Node Dissection and to identify independent risk factors for their development.
Inclusion: Age ≥18 years; Clinical stage IA-IIIB NSCLC (TNM 8th edition), oncologically radical resection is planned: anatomical segmentectomy/lobectomy/bilobectomy/pneumonectomy (including sleeve resection); LND (systematic) is performed with mandatory inclusion of group 7 (subcarinal) lymph nodes; Signed informed consent from all study patients.
Exclusion: "Wedge" surgery without any lymph node dissection; Nonemergency surgery; conversion is acceptable; Patients who cannot complete 30 days of observation (no contact, etc.) should be excluded prior to surgery; Small cell lung cancer, benign and metastatic tumors.